Clin Adv Hematol Oncol. 2016 Sep;14(9):728.
An article in the July 2016 issue, "Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma" by Gaurav Varma, MSPH, Tyler P. Johnson, MD, and Ranjana H. Advani, MD, described ONO/GS-4059 as a "reversible" inhibitor of BTK when it is in fact an "irreversible" inhibitor. We have made the correction to pages 546 and 552 of the online version at www.hematologyandoncology.net. Many thanks to an astute reader for pointing out the error. This corrects the article pmid:27379948.
2016年7月期的一篇文章《布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病和淋巴瘤中的应用》，作者为公共卫生硕士高拉夫·瓦尔马、医学博士泰勒·P·约翰逊和医学博士兰贾娜·H·阿德瓦尼，文中将ONO/GS - 4059描述为布鲁顿酪氨酸激酶（BTK）的“可逆”抑制剂，而实际上它是一种“不可逆”抑制剂。我们已在www.hematologyandoncology.net的在线版本第546页和第552页进行了更正。非常感谢一位敏锐的读者指出这个错误。这更正了文章，其医学主题词（PMID）为：27379948。
